Source-grounded facts extracted from BIO KEY INTERNATIONAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO KEY INTERNATIONAL INC reported first quarter 2026 results: revenue $2.15M, net income $(165K). Guidance raised.
“Q1’26 revenues increased 34% to $2.15M vs. Q1’25 and 74% vs. Q4’25 ● Q1’26 net loss improved to $(165K) vs. $(737K) in Q1’25 and $(1.722M) in Q4’25”
BIO KEY INTERNATIONAL INC received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
“May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)”
BIO KEY INTERNATIONAL INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)”
BIO KEY INTERNATIONAL INC: Certificate of Amendment filed to effect a 1-for-10 reverse stock split of common stock, approved by stockholders on April 20, 2026 and filed on April 28, 2026 (effective 2026-04-29).
“the Company filed a Certificate of Amendment (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware to effect the reverse stock split. The Certificate of Amendment will become effective at 5:00 p.m., Eastern Time, on April 29, 2026.”
BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 16, 2026, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025. The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.”
BIO KEY INTERNATIONAL INC reported 1H'26 (first half of 2026) ending June 30, 2026 results: revenue 50% to approximately $5M vs. $3.3M in 1H'25, net income Positive net income expected in 1H'26 vs. $1.9M net loss in 1H'25. Guidance initiated.
“previewed today its business outlook for the first half of 2026 (1H’26) ending June 30, 2026, supported by building software license momentum and strength in hardware revenues. Expected 1H ’ 26 Results: ● 1H’26 revenues expected to grow 50% to approximately $5M vs. $3.3M in 1H’25 ● Positive net income expected in 1H’26 vs. $1.9M net loss in 1H’25”
BIO KEY INTERNATIONAL INC reported financial results for fourth quarter and year ending December 31, 2025.
“On March 31,2026, BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and year ending December 31, 2025.”
BIO KEY INTERNATIONAL INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 6, 2025, the Company received a letter from Nasdaq (the “ Letter ”) stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until May 4, 2026, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimu”
BIO KEY INTERNATIONAL INC issued 429,027 shares of common stock to Streeterville Capital, LLC.
“exchange (the “Exchange”) the Partitioned Notes for an aggregate of 429,027 shares (the “Exchange Shares”) of the Company’s Common Stock”
BIO KEY INTERNATIONAL INC issued 6,183,336 shares of warrant to existing institutional investor for combined purchase price of $0.25 per Existing Warrant.
“Warrants, subject to compliance with the beneficial ownership limitations included in the Existing Warrants, and the payment by the Investor of the combined purchase price of $0.25 per Existing Warrant (the “New Warrant Consideration”), the Investor received new unregistered warrants to purchase up to an aggregate of 6,183,336 shares of the Company’s Common”
BIO KEY INTERNATIONAL INC issued 3,091,668 shares of common stock to existing institutional investor.
“On October 27, 2025, BIO-key International, Inc. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing institutional investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of 3,091,668 shares of the Company’s common stock”
BIO KEY INTERNATIONAL INC incurred senior notes of $1,130,000 principal amount senior secured promissory note with Streeterville Capital, LLC at nine percent (9%) per annum maturing eighteen months following the date of issuance.
“On September 30, 2025, BIO-key International, Inc. (the “Company,” “we” or “us”) entered into and closed a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC, an existing lender of the Company (the “Lender”), which provided for the issuance of a $1,130,000 principal amount senior secured promissory note (the “Note”).”
BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 9, 2025, the Company received notice from the staff of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company’s closing bid price for the last 30 consecutive business days was less than $1.00 per share. As a result, the Company does not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification had no immediate effect on the listing or trading of the common stock on the Nasdaq Capital Market. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 1”
BIO KEY INTERNATIONAL INC received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).
“April 24, 2025, the Company received notice from Nasdaq stating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) and that the matter has been closed.”
BIO KEY INTERNATIONAL INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“April 17, 2025, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“ SEC ”), due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “ Form 10-K ”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Na”
BIO KEY INTERNATIONAL INC engaged Bush & Associates CPA as its auditor.
“(the “ Company ”) approved the engagement of Bush & Associates CPA (“ Bush & Associates ”) as the Company’s independent registered public accounting firm and on April 23, 2024, dismissed Marcum LLP (“ Marcum ”), as the Company’s independent registered public accounting firm. Marcum was retained to serve as the Company’s independent registered public accounting firm on July 20, 2022.”
BIO KEY INTERNATIONAL INC dismissed Marcum LLP as its auditor.
“(the “ Company ”) approved the engagement of Bush & Associates CPA (“ Bush & Associates ”) as the Company’s independent registered public accounting firm and on April 23, 2024, dismissed Marcum LLP (“ Marcum ”), as the Company’s independent registered public accounting firm.”
BIO KEY INTERNATIONAL INC reported that prior financial statements should not be relied upon.
“months ended June 30, 2023, and the three and nine months ended September 30, 2023 included in the Company’s previously filed Quarterly Reports on Form 10-Q for such periods (collectively, the “ Financial Statements ”) should no longer be relied upon. Similarly, any previously issued or filed reports, press releases, earnings releases, or other communications describing the Company’s financial statements and other related financial information covering the forgoing periods and the year ended December 31, 2023, including the Company’s Notification of Late Filing on SEC Form 12b-25 filed on April 2, 2024 and the Company’s April 1, 2024 press release, should no longer be relied upon. In the course of the audit of the Company’s consolidated financial statements for the fiscal year ended December 31, 2023, the Company determined that certain errors were made which require the restatement of”
BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 17, 2024, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“ SEC ”), due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “ Form 10-K ”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on”
BIO KEY INTERNATIONAL INC reported fourth quarter ended December 31, 2023 results: net income $(4.1M), EPS $(5.54) per share.
“Likewise, in Q4’23 BIO-key reduced its net loss more than 40% to $(4.1M), or $(5.54) per share, from $(6.7M), or $(14.58) per share in 2023.”
BIO KEY INTERNATIONAL INC reported year ended December 31, 2023 results: revenue $9.1M, net income $(6.2M), EPS $(11.45) per share.
“Exhibit 99.1 Identity and Access Management Software Provider BIO-key Preliminary 2023 Results: Operating Loss Trimmed Approx. $3.5M on Approx. 29% Revenue Growth to $9.1M; Investor Call Tomorrow at 10am ET Holmdel, NJ – April 1, 2024 – BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and”
BIO KEY INTERNATIONAL INC: Approved amendment to Certificate of Incorporation to effect a 1-for-18 reverse stock split, effective December 20, 2023 (effective 2023-12-20).
“At the above referenced Special Meeting, stockholders of the Company approved an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Common Stock in the range of 1-for-6 to 1-for-20, with the final decision of whether to proceed with the reverse stock split and the exact ratio and timing of the reverse stock split to be determined by the Board, in its discretion, no later than December 22, 2023”
BIO KEY INTERNATIONAL INC shareholders approved Proposal 2: BIO-key International, Inc. 2023 Stock Incentive Plan at the 2023-12-14 meeting.
“The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,869,452 856,044 26,708 2,702,882”
BIO KEY INTERNATIONAL INC shareholders approved Proposal 1: Amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-6 and 1-for-20 at the 2023-12-14 meeting.
“The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 6,139,952 1,283,994 31,140 -”
Thomas E. Bush, III resigned as Director at BIO KEY INTERNATIONAL INC.
“On November 8, 2023, Thomas E. Bush, III notified BIO-key International, Inc. (the “ Company ”) that he would be resigning from the Board of Directors of the Company effective November 8, 2023.”
BIO KEY INTERNATIONAL INC entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-10-30).
“On October 30, 2023, the Company entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Maxim Group LLC to serve as its exclusive placement agent in connection with the Offering.”
BIO KEY INTERNATIONAL INC entered into Purchase Agreement with certain investors (effective 2023-10-30).
“On October 30, 2023, BIO-key International, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors in connection with a public offering of the Company’s securities (the “ Offering ”).”
BIO KEY INTERNATIONAL INC reported three and nine months ended September 30, 2023 results: revenue $1.8M, EPS ($0.08).
“(EXHIBIT 99.1) --- EX-99.1 2 ex_585492.htm EXHIBIT 99.1 ex_585492.htm Exhibit 99.1 Digital Authentication and Identity Provider BIO-key Sees Q3 Revenues Rising over 30% to $1.8M on Strength in Software License Fees, Services and Hardware Sales Holmdel, NJ – October 25, 2023 - BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of”
BIO KEY INTERNATIONAL INC reported second quarter ended June 30, 2023 results: revenue $1.9M, net income $1.4M.
“filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ex_560801.htm EXHIBIT 99.1 ex_560801.htm Exhibit 99.1 Identity and Access Management Provider BIO-key Reports Q2 Revenue of $1.9M; Hosts Investor Call Tomorrow, August 15 th at 10am ET WALL, NJ – August 14, 2023 - BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and”
BIO KEY INTERNATIONAL INC shareholders approved Advisory vote on compensation of named executive officers at the 2023-07-24 meeting.
“3. Proposal to approve, on a non-binding and advisory basis, the compensation paid to the Company’s named executive officers. The proposal was approved and the final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 2,117,139 588,218 63,586 2,740,194”
BIO KEY INTERNATIONAL INC shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-07-24 meeting.
“2. Proposal to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The proposal was approved and the final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 4,139,367 1,294,602 75,168 0”
BIO KEY INTERNATIONAL INC shareholders approved Election of directors for a one-year term at the 2023-07-24 meeting.
“1. Proposal to elect the following nominees to serve as members of the Company’s board of directors for a one-year term: Michael W. DePasquale, Wong Kwok Fong (Kelvin), Thomas E. Bush, III, Robert J. Michel, Emmanuel Alia, and Cameron E. Williams. Each of the nominees were elected and the final voting results were as follows: Name Votes For Withheld Broker Non-Votes Michael DePasquale 2,257,370 511,573 2,740,194 Wong Kwok Fong (Kelvin) 2,261,052 507,891 2,740,194 Thomas E. Bush, III 2,275,350 495,593 2,740,194 Robert J. Michel 1,783,395 985,548 2,740,194 Emmanuel Alia 2,056,284 712,659 2,740,194 Cameron E. Williams 1,776,537 992,406 2,740,194”
BIO KEY INTERNATIONAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“July 12, 2023, the Company received a letter from Nasdaq (the “Letter”) stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until January 8, 2024, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum”
BIO KEY INTERNATIONAL INC amended Waiver and Amendment No. 1 to Securities Purchase Agreement with AJB Capital Investments, LLC (effective 2023-06-22).
“On June 22, 2023, BIO-key International, Inc. (the “Company,” “we” or “us”) entered into a Waiver and Amendment No. 1 to Securities Purchase Agreement (the “Amendment”) with AJB Capital Investments, LLC (the “Investor”).”
Cameron E. Williams was appointed as Director at BIO KEY INTERNATIONAL INC.
“On June 2, 2023, Cameron E. Williams was appointed to serve on the Board of Directors (the “Board) of BIO-key International, Inc. (the “Company”).”
BIO KEY INTERNATIONAL INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“May 23, 2023, BIO-key International, Inc. (the “Company”) received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”), due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “Form 10-Q”). As previously reported, on April 18, 2023 the Company was notified by Nasdaq that is was not”
BIO KEY INTERNATIONAL INC reported first quarter ended March 31, 2023 (Q1’23) results: revenue $3.1M, net income $0.5M, EPS $0.06 per share.
“March 31, 2023 (Q1’23). BIO-key will host an investor call today at 10:00 a.m. ET (details below) to review its results and outlook. Highlights: ● Q1 ’ 23 revenues grew 59% to $3.1M , reflecting a growing base of high-margin, annual recuring revenue (ARRs) and new customer wins. ● Continued strength in higher education IAM deployments at colleges in”
BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 18, 2023, BIO-key International, Inc. (the “Company”) received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”), due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nas”
Pieter Knook resigned as Director at BIO KEY INTERNATIONAL INC.
“On April 14, 2023, Pieter Knook notified BIO-key International, Inc. (the “Company”) that he would be resigning from the Board of Directors of the Company effective May 13, 2023.”
BIO KEY INTERNATIONAL INC reported the year ended December 31, 2022 results: revenue $7.0M. Guidance initiated.
“FY’22 revenue increased 37% to $7.0M from $5.1M in FY’21”
BIO KEY INTERNATIONAL INC reported the fourth quarter ended December 31, 2022 results: revenue $1.76M. Guidance initiated.
“Q4’22 revenue increased 88% to $1.76M from $0.93M in Q4’21”
Thomas Gilley resigned as Director at BIO KEY INTERNATIONAL INC.
“On February 9, 2023, Thomas Gilley notified BIO-key International, Inc. (the “Company”) that he would be resigning from the Board of Directors of the Company effective February 9, 2023.”
BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 12, 2023, BIO-key International, Inc. (the “Company”), received a letter (the “Letter”) from the staff of The Nasdaq Capital Market LLC (the “Nasdaq Capital Market”) stating that the Company’s closing bid price for the last 30 consecutive business days was less than $1.00 per share. As a result, the Company does not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification had no immediate effect on the listing or trading of the common stock on the Nasdaq Capital”
BIO KEY INTERNATIONAL INC reported third quarter ended September 30, 2022 results: revenue $1.4M, net income $2.4M, EPS $0.29 per share. Guidance lowered.
“--- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ex_447392.htm EXHIBIT 99.1 ex_447392.htm Exhibit 99.1 Cyber-Security Provider BIO-key Reports Q3 and Year-to-Date Revenues Rose to $1.4M and $5.3M, Respectively, on Growing Software and Services Revenue; Investor Call Tomorrow at 10am ET WALL, NJ – November 14, 2022 - BIO-key ® International, Inc. (Nasdaq: BKYI),”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.